Neumann Mark — SEC Form 4 filings
SEC reporting owner CIK 1756211. 11 Form 4 filings on record with FilingPulse; latest filed 2026-02-05.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-02-05 to 2026-02-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 4 filings — 58,958 shares, $4,112,015 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: sale of 18,714 shares @ $75.08 ($1,405,047) in Intra-Cellular Therapies, Inc., filed 2024-08-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Intra-Cellular Therapies, Inc. (ITCI) | EVP, Chief Commercial Officer | 10 | — | 12 legs · 58,958 sh · $4,112,015 | 31 |
| Veradermics, Inc (MANE) | Chief Commercial Officer | 1 | — | — | 1 |
Form 4 filings — Neumann Mark
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-05 | 4 | Veradermics, Inc (MANE) | Grant/award (A): 102,885 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Disposition to issuer (D): 52,811 @ $132 · Disposition to issuer (D): 17,916 (derivative) · Disposition to issuer (D): 13,133 (derivative) · Disposition to issuer (D): 17,485 (derivative) · Disposition to issuer (D): 22,727 (derivative) · Grant/award (A): 13,134 (derivative) @ $0 · +3 more | EDGAR |
| 2025-03-10 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 13,133 · Tax withholding (F): 5,572 @ $131.19 · Option exercise (M): 7,345 · Tax withholding (F): 3,116 @ $131.24 · Option exercise (M): 13,133 (derivative) @ $0 · Option exercise (M): 7,345 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 8,742 · Tax withholding (F): 3,709 @ $128.20 · Option exercise (M): 8,742 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 11,017 @ $0 · Tax withholding (F): 4,729 @ $127 · Grant/award (A): 22,727 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 18,714 @ $36.89 · Sale (S): 18,714 @ $75.08 · Option exercise (M): 18,714 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Sale (S): 8,636 @ $66.37 · Sale (S): 4,496 @ $66.95 · Option exercise (M): 7,345 · Sale (S): 4,303 @ $65.11 · Sale (S): 1,729 @ $65.92 · Sale (S): 1,313 @ $66.86 · +1 more | EDGAR |
| 2024-03-08 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 13,132 · Option exercise (M): 13,132 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 26,227 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 7,907 · Sale (S): 200 @ $68.03 · Sale (S): 4,059 @ $69.56 · Sale (S): 2,341 @ $70.70 · Sale (S): 1,307 @ $71.18 · Option exercise (M): 7,907 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 11,860 @ $0 · Sale (S): 4,956 @ $66.67 · Sale (S): 6,904 @ $67.49 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1756211 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →